Evidence gap on antihyperglycemic pharmacotherapy in frail older adults : A systematic review.

Bollig, Claudia; Torbahn, Gabriel; Bauer, Jürgen; Brefka, Simone; Dallmeier, Dhayana; Denkinger, Michael; Eidam, Annette; Klöppel, Stefan; Zeyfang, Andrej; Voigt-Radloff, Sebastian (2021). Evidence gap on antihyperglycemic pharmacotherapy in frail older adults : A systematic review. Zeitschrift für Gerontologie und Geriatrie, 54(3), pp. 278-284. Springer 10.1007/s00391-020-01724-3

Preview

Text Bollig2020_Article_EvidenceGapOnAntihyperglycemic.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (385kB) | Preview

BACKGROUND

Although antihyperglycemic pharmacotherapy in frail older adults with type 2 diabetes mellitus (T2DM) is challenging, recommendations from international guidelines are mainly based on indirect evidence from trials not including frail participants.

OBJECTIVE

This systematic review investigated the effectiveness and safety of pharmacotherapy in frail older adults with T2DM.

MATERIAL AND METHODS

Randomized (RCT) and non-randomized prospective clinical trials (non-RCT) were searched in three electronic databases (Medline, Embase, Central) up to October 2018. Trials in older adults with T2DM who were assessed as significantly or severely impaired by defined cut-off scores of assessment instruments on frailty, activities of daily living or physical functional impairment were included.

RESULTS

Two reviewers independently screened 17,391 references for inclusion and assessed risk of bias with ROBINS‑I. Five non-RCTs and no RCT were identified. Treatment of T2DM without insulin compared to insulin could be associated with increased improvement in cardiac functions in patients with cardiac resynchronization therapy and with decreased falls in frail older women. While better glycemic control with low variability and low HbA1c (hemoglobin A1c) values (<7%) was associated with better maintenance of physical function in community-dwelling older persons, higher HbA1c values (8-8.9%) were associated with a reduction in the composite outcome of death or functional decline in community-dwelling diabetic older adults with need for skilled assistance. Due to serious risk of bias in all studies, results should be considered with caution.

CONCLUSION

Well-designed, large-scale RCTs including this important group of patients are required to assess the effectiveness and safety of pharmacotherapy and HbA1c targets.

Interest & Impact

Downloads

124 since deposited on 05 May 2020
13 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item